Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc.

ANEB·NASDAQ

$1.72

-33%
HealthcareBiotechnology

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

At a Glance

Live Snapshot
Market Cap$70.67M
EPS-0.2500
P/E Ratio-5.74
Earnings Date02/12/2026

aneb

Net Common Stock Issuance

Last Annual Value

14.88M

3-Year CAGR

%

5-Year CAGR

38%

10-Year CAGR

17%

Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Competitors Analysis of Net Common Stock Issuance

ANEB · NASDAQ
CompanyNet Common Stock Issuance
CAGR 3Y
CAGR 5Y
CAGR 10Y
14.88M
30.8%-8.2%N/A 
CLNN logo
Clene Inc.
NASDAQ:CLNN
10.40M
-37.2%2.4%N/A
107.39M
89.8%41.9%N/A
-4.28M
N/AN/AN/A
66.55M
0.0%-9.6%N/A
67.90M
-25.1%-15.0%N/A
EXOZ logo
eXoZymes, Inc.
NASDAQ:EXOZ
0.00
N/AN/AN/A
105.42M
N/AN/AN/A
-4.74M
N/AN/AN/A
225.00K
14.7%-49.4%N/A
50.07M
-2.3%N/AN/A
Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Fair Value Envelope

ANEB · NASDAQ

Our analysis suggests that ANEB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.72, this represents a potential HIDDEN relative to our calculated worth for Anebulo Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $1.72